menu
    • menu
    [{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydromethylthionine Mesylate

    Menu

    Hydromethylthionine Mesylate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    TauRx Submits UK Marketing Application for HMTM as Alzheimer’s Disease Treatment

    Details : TRx0237 (hydromethylthionine mesylate), is an investigational small molecule Tau protein inhibitor, for the treatment of mild to moderate Alzheimer’s disease. The company has submitted MAA in UK.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    July 01, 2024

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    TauRx's LUCIDITY Trial Indicates Two-Year Sustained Cognitive Benefits of HMTM

    Details : TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase 3 clinical trial studies for the treatment of Alzheimer's disease.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 07, 2024

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    LUCIDITY Phase 3 Topline Data Presented At CTAD For HMTM - The Only Oral Anti-Tau Therapy In Late-stage Develo...

    Details : TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 30, 2022

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    TauRx Announces Additional Investment of USD119 Million Following Announcement Of Phase 3 LUCIDITY Topline Res...

    Details : HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 14, 2022

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submi...

    Details : For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 06, 2022

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauR...

    Details : TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 01, 2022

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    TauRx's Late-Stage Clinical Trial Reaches New Milestone

    Details : This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 14, 2022

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed

    TauRx Therapeutics

    Singapore arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia

    Details : Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.

    Product Name : TRx0237

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 19, 2020

    Lead Product(s) : Hydromethylthionine Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth